UMIN-CTR History

Name：　　UMIN ID：


Unique ID issued by UMIN UMIN000008145
Receipt number R000008601
Scientific Title Phase 2 study evaluating the efficacy and safety of the combination of Bendamustine, Rituximab and Dexamethazone (RBenda-D) for treatment of CD20-positive relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.
Date of disclosure of the study information 2012/06/12
Last modified on 2019/10/20 12:16:46

No. Disposal Last modified on Item of update
1 Insert 2012/06/12 13:50:30
2 Update 2016/06/15 21:05:45 Recruitment status
3 Update 2016/12/15 12:23:01 Email
Name of primary person or sponsor
Organization
4 Update 2016/12/15 12:37:04 Key inclusion criteria
5 Update 2019/04/05 18:13:13 Date of IRB
Anticipated trial start date
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
6 Update 2019/06/17 15:29:39 1st name of lead principal investigator
Last name of lead principal investigator
1st name of lead principal investigator
Last name of lead principal investigator
Organization
Zip code

Last name of contact person

Last name of contact person
Zip code
Organization
Organization
Address
Address
Tel
Email
7 Update 2019/06/18 07:52:51 URL releasing protocol
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results
Results date posted
Date of the first journal publication of results
Baseline Characteristics
Baseline Characteristics
Participant flow
Participant flow
Adverse events
Adverse events
Outcome measures
Outcome measures
8 Update 2019/06/18 07:53:42 Recruitment status
9 Update 2019/06/18 07:54:09 Publication of results
10 Update 2019/06/18 08:03:40
11 Update 2019/06/18 08:04:28 Participant flow
12 Update 2019/10/20 12:16:46 Results